Phase I/II Calcitriol in Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00794547
Recruitment Status : Terminated
First Posted : November 20, 2008
Results First Posted : May 5, 2014
Last Update Posted : December 12, 2017
Information provided by (Responsible Party):
University of Michigan Cancer Center

Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Calcitriol

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Phase 1

In the Phase I part of the study, we will test the safety of calcitriol along with standard chemotherapy. In addition, the goal is to see what effects (good and bad) it has on you and your type of Non-Small Cell Lung Cancer. This study is ongoing. In this portion of the study, we are testing increasing doses of calcitriol in combination with standard chemotherapy. If 2/3 patients at any dose level experience side effects that are limiting, we will call the dose level below that dose the maximum tolerated dose.

Calcitriol: Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.

Phase 2

In the Phase II part of the study, we will find out the response of subjects' cancer has to the combination of a fixed dose of calcitriol (determined in the phase I study) with standard chemotherapy.

Calcitriol: In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy

Participant Flow:   Overall Study
    Phase 1   Phase 2
STARTED   18   16 
COMPLETED   18   16 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Thirty-four patients were enrolled (18 in phase I and 16 in phase II).

Reporting Groups
Calcitriol + Cisplatin + Docetaxel Calcitriol, administered IV at 30, 45, 60, 80, or 100 mcg/m^2 (every 21 days), along with Cisplatin, 75 mg/m^2 (every three weeks), and Docetaxel, 75 mg/m^2 (every three weeks).

Baseline Measures
   Calcitriol + Cisplatin + Docetaxel 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Median (Full Range)
 (34 to 79) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      22  64.7% 
Male      12  35.3% 
Region of Enrollment 
[Units: Participants]
United States   34 
Histology [1] 
[Units: Participants]
Adenocarcinoma   21 
Squamous carcinoma   12 
[1] Tumor histology results. Categories include Adenocarcinoma, Squamous Carcinoma and Non-Small-Cell Lung Cancer Not Otherwise Specified (NSCLC NOS).
Performance Status [1] 
[Units: Participants]
Performance Status 0   16 
Performance Status 1   18 
[1] Eastern Cooperative Oncology Group Performance Status at baseline. Scores may be 0 (Asymptomatic; fully active, able to carry on all predisease activities without restriction) or 1 (Symptomatic but completely ambulatory; restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work)
Smoking Status 
[Units: Participants]
Never Smoker   2 
Ever Smoker   29 
Unknown   3 

  Outcome Measures

1.  Primary:   MTD of Intravenous Calcitriol When Administered Prior to Fixed Dose Cisplatin 75mg/m2 and Docetaxel 75 mg/m2, Every 3 Weeks in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)   [ Time Frame: 5 years ]

2.  Primary:   Number of Participants That Experience Grade 3 or Greater Neutropenia   [ Time Frame: 30 days after last dose ]

3.  Primary:   Median Time to Progression   [ Time Frame: 5 years ]

4.  Primary:   Median Overall Survival   [ Time Frame: 5 years ]

5.  Secondary:   Mean AUC 1,25-D3 Concentration at 12 and 24 Hours   [ Time Frame: 12 and 24 hours post dose ]

6.  Other Pre-specified:   To Correlate the Pharmacokinetic Parameters of Systemic Calcitriol Exposure (AUC) With SNPs of the 24-hydroxylase (CYP24), the Major Vitamin D3 Inactivating Enzyme.   [ Time Frame: 3-6 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Nithya Ramnath
Organization: University of Michigan Comprehensive Cancer Center
phone: 734-647-1417

Publications of Results:

Responsible Party: University of Michigan Cancer Center Identifier: NCT00794547     History of Changes
Obsolete Identifiers: NCT00470431
Other Study ID Numbers: UMCC 2008.042
HUM 21242 ( Other Identifier: University of Michigan Medical IRB )
First Submitted: November 19, 2008
First Posted: November 20, 2008
Results First Submitted: March 31, 2014
Results First Posted: May 5, 2014
Last Update Posted: December 12, 2017